Lyketsos C G, Baker L, Warren A, Steele C, Brandt J, Steinberg M, Kopunek S, Baker A
Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
J Neuropsychiatry Clin Neurosci. 1997 Winter;9(1):64-7. doi: 10.1176/jnp.9.1.64.
The apolipoprotein E (APOE) locus on chromosome 19 has been shown to modify risk, and age at onset, of Alzheimer's disease (AD). The authors hypothesized that the phenotypic expression of different psychiatric symptoms in patients with AD would be associated with variability in APOE locus. Neuropsychiatric and genetic testing of 120 probable AD patients revealed 28% had major depression, 17% had minor depression, 30% had delusions, and 14% had hallucinations; 69% were carriers of at least one APOE E4 allele (14% homozygous E4/E4, 49% heterozygous E3/E4, 6% heterozygous E2/E4, 29% homozygous E3/E3, 2% heterozygous E2/E3). Prevalence of the various psychiatric disturbances did not differ significantly in AD patients with different APOE genotypes. Apolipoprotein E does not appear to modify the risk of developing AD-associated psychiatric symptomatology.
19号染色体上的载脂蛋白E（APOE）基因座已被证明会影响阿尔茨海默病（AD）的发病风险和发病年龄。作者推测，AD患者不同精神症状的表型表达与APOE基因座的变异性有关。对120例可能患有AD的患者进行的神经精神和基因检测显示，28%的患者患有重度抑郁症，17%的患者患有轻度抑郁症，30%的患者有妄想，14%的患者有幻觉；69%的患者携带至少一个APOE E4等位基因（14%为E4/E4纯合子，49%为E3/E4杂合子，6%为E2/E4杂合子，29%为E3/E3纯合子，2%为E2/E3杂合子）。不同APOE基因型的AD患者中各种精神障碍的患病率没有显著差异。载脂蛋白E似乎不会改变发生AD相关精神症状的风险。
